Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
Eli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a head-to-head trial, albeit in diabetes rather than obesity. The drug ...
October 28, 2026 06:45 AM EDT R&DGLP-1 drugs Lilly's triple-G outshines Novo's Ozempic in diabetes Elizabeth Cairns Senior biopharma journalist Eli Lilly’s retatrutide, the incretin shot that has already proven its effectiveness against other assets on a cross-trial basis, has cemented its utility in a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that